24 June 2019 In General Health

There is much literature on the topic of wine and health dating back to the days of Hippocrates, and it is believed that there are unlimited varieties of wine, allowing the association of senses, nutrition, and hedonism [...].

24 June 2019 In General Health

BACKGROUND: Alcohol use is a leading risk factor for global disease burden, and data on alcohol exposure are crucial to evaluate progress in achieving global non-communicable disease goals. We present estimates on the main indicators of alcohol exposure for 189 countries from 1990-2017, with forecasts up to 2030.

METHODS: Adult alcohol per-capita consumption (the consumption in L of pure alcohol per adult [>/=15 years]) in a given year was based on country-validated data up to 2016. Forecasts up to 2030 were obtained from multivariate log-normal mixture Poisson distribution models. Using survey data from 149 countries, prevalence of lifetime abstinence and current drinking was obtained from Dirichlet regressions. The prevalence of heavy episodic drinking (30-day prevalence of at least one occasion of 60 g of pure alcohol intake among current drinkers) was estimated with fractional response regressions using survey data from 118 countries.

FINDINGS: Between 1990 and 2017, global adult per-capita consumption increased from 5.9 L (95% CI 5.8-6.1) to 6.5 L (6.0-6.9), and is forecasted to reach 7.6 L (6.5-10.2) by 2030. Globally, the prevalence of lifetime abstinence decreased from 46% (42-49) in 1990 to 43% (40-46) in 2017, albeit this was not a significant reduction, while the prevalence of current drinking increased from 45% (41-48) in 1990 to 47% (44-50) in 2017. We forecast both trends to continue, with abstinence decreasing to 40% (37-44) by 2030 (annualised 0.2% decrease) and the proportion of current drinkers increasing to 50% (46-53) by 2030 (annualised 0.2% increase). In 2017, 20% (17-24) of adults were heavy episodic drinkers (compared with 1990 when it was estimated at 18.5% [15.3-21.6%], and this prevalence is expected to increase to 23% (19-27) in 2030.

INTERPRETATION: Based on these data, global goals for reducing the harmful use of alcohol are unlikely to be achieved, and known effective and cost-effective policy measures should be implemented to reduce alcohol exposure.

FUNDING: Centre for Addiction and Mental Health and the WHO Collaborating Center for Addiction and Mental Health at the Centre for Addiction and Mental Health.

24 June 2019 In General Health

The scientific evidence available on the association between moderate alcohol intake and levels of blood cardiometabolic markers is still inconsistent and difficult to interpret for future disease prevention. However, we hypothesize that moderate consumption of alcohol is associated with lower levels of inflammation markers and higher levels of protective cardiometabolic markers. Thus, this work aimed to examine the associations of moderate alcohol intake and the type of alcoholic beverage with metabolic and inflammatory biomarkers. An observational, cross-sectional study including 143 apparently healthy adults 55years of age and older was performed. Interviewer-administered questionnaires were used to collect information on alcoholic beverage intake frequency, food frequency, physical activity, socioeconomic status, diseases and medications, and other health-related habits. Three groups were established prior to recruitment: (1) abstainers and occasional consumers (ABS, n=54); (2) beer consumers (BEER >/=80% of total alcohol intake; n=40), and (3) mixed beverage consumers (MIXED; n=49). Univariate analysis of variance models, adjusted for confounding factors and covariables, were performed. High-density lipoprotein cholesterol (HDL-c) and sP-selectin were significantly higher in the MIXED group than in the ABS group, and adiponectin was higher in the MIXED group compared to the BEER group. All alcohol consumers also had higher mean platelet volume values compared to ABS. In linear regression analyses, HDL-c, sP-selectin, and adiponectin were positively associated with wine intake (g/d) (P<.001, P=.014, and P=.017, respectively); and mean platelet volume, with beer intake (P=.017). In conclusion, this cross-sectional study showed that moderate alcohol intake is associated with higher levels of HDL-c and adiponectin compared to those in abstainers, which are mainly explained by wine intake.

24 June 2019 In General Health

Wine, a widely consumed beverage, comprises several biophenols that promote health. Flavonoids, majorly present in red wine, have been shown to have antioxidant, anti-inflammatory, anticancer, and immunomodulatory activities. Regular consumption of red wine (100 mL/day) is estimated to provide an average of 88 mg of flavonoids, whereas recent epidemiological studies indicate that wine is one of the major sources of flavonoid intake amongst wine lovers in European countries (providing an average intake of 291(-)374 mg/day of flavonoids). In addition to being antioxidants, in vitro studies suggest that flavonoids also have anti-allergic activities that inhibit IgE synthesis, activation of mast cells and basophils or other inflammatory cells, and production of inflammatory mediators, including cytokines. Furthermore, they affect the differentiation of naive CD4+ T cells into effector T cell subsets. Moreover, several studies have reported the benefits of flavonoids in allergic models such as atopic dermatitis, asthma, anaphylaxis, and food allergy; however, evidence in humans is limited to allergic rhinitis and respiratory allergy. Although further evaluation is required, it is expected that an appropriate intake of flavonoids may be beneficial in preventing, and eventually managing, allergic diseases.

Page 6 of 35

Contact us

We love your feedback. Get in touch with us.

  • Tel: +32 (0)2 230 99 70
  • Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


The authors have taken reasonable care in ensuring the accuracy of the information herein at the time of publication and are not responsible for any errors or omissions. Read more on our disclaimer and Privacy Policy.